- Home
- ANTA vs ACIU Comparison
ANTA vs ACIU Comparison
Compare ANTA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | ACIU |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.7M | 213.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ANTA | ACIU |
|---|---|---|
| Price | $8.40 | $2.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.50 | $10.00 |
| AVG Volume (30 Days) | 6.6K | ★ 316.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $67.65 | N/A |
| Revenue Next Year | $59.30 | $495.67 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.35 | $1.43 |
| 52 Week High | $15.65 | $4.00 |
Technical Indicators
Market Signals| Indicator | ANTA | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 42.65 |
| Support Level | N/A | $2.54 |
| Resistance Level | $9.98 | $3.92 |
| Average True Range (ATR) | 0.33 | 0.19 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 2.61 | 55.00 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.